The Mandatory Problem Reporting Form: Myanmar’s Vigilance Reporting Mechanism

1. Key takeaways

Medical device vigilance in Myanmar centres on the Mandatory Problem Reporting Form, which is specifically provided for in Section 8 of the Technical Guidelines for the e-Submission of Medical Devices. Together with the Product Safety Declaration in Section 6 and the Declaration of Conformity in Section 7, this form constitutes the documentary system that accompanies Myanmar devices before and after they reach the market.

GRZAN note: the word “mandatory” shows that this report is not a voluntary feedback channel but a legally prescribed reporting format. When building a vigilance system, companies should adopt the form format specified in the guidelines directly, rather than designing their own reporting templates. A self-designed template, however well intentioned, risks omitting fields the authority expects to see, and any omission creates a gap that must later be filled under time pressure, usually during an inquiry when the company is least able to negotiate. The practical rule is simple: use the official form, fill it completely, and file it through the prescribed channel.

2. Legal basis

The table below sets out the origin of the form, its place in the documentary system, and its relationship with the monitoring layers and the submission channel. Note that the form sits inside a nine-part guideline whose middle sections prescribe the official formats, which is why format discipline matters across the whole dossier.

3. Expert insights

Insight 1: Sections 5 to 8 form the “format document group” for Myanmar devices. The letter of authorisation, the product safety declaration, the declaration of conformity and the mandatory problem reporting form all have official formats. This shows that Myanmar exercises fairly strict control over documentary form, not only over documentary substance. Companies used to markets where free-form cover letters are tolerated should recalibrate: in Myanmar, the format itself is part of the requirement, and deviation from it invites clarification requests.

Insight 2: the very existence of a mandatory problem reporting form confirms the statutory character of the vigilance duty. If reporting were merely encouraged, there would be no need to prescribe a dedicated form and embed it in the e-Submission guideline structure. The form’s position in Section 8, alongside authorisation and conformity documents, signals that problem reporting belongs to the same compliance tier as registration paperwork, not to the informal periphery.

Insight 3: the reporting obligation and withdrawal measures interlock. Failure to perform the duty of supervising adverse effects can constitute a ground for withdrawal from circulation, forming a closed loop between obligation and consequence. This linkage matters for planning: a reporting lapse is not only a procedural shortcoming but can escalate into loss of market access, which is the most expensive outcome a compliance lapse can produce. The escalation is avoidable at every stage, provided the reporting loop is closed in the first place.

Insight 4: reporting subjects cover manufacturers and registration certificate holders. This connects with the authorised representative system: reports flow through the local entity. Foreign manufacturers should therefore ensure that their authorised representative agreement expressly covers the transmission of problem reports, including who drafts, who submits and who retains the receipts, so that responsibility does not fall between the two parties when an event occurs. An untested handover is discovered precisely when it cannot be repaired.

Insight 5: vigilance data and post-market sampling results corroborate each other. The authority can cross-compare findings from proactive sampling with information from passive reports. A discrepancy in either direction attracts attention: sampling findings without corresponding reports suggest under-reporting, while reports describing problems that sampling never detects are a reminder that shelf testing and field performance are different windows on the same product. Consistency between the two channels is therefore itself a compliance indicator, and companies should audit it internally before the authority does.

4. Practical recommendations

• Adopt the form format prescribed in Section 8 of the guidelines directly. Do not design a custom reporting template, however convenient it may seem internally; format deviation is a self-inflicted finding.
• Build a closed-loop process from problem identification to assessment to reporting. Define the responsible person for each stage, so that no event stalls in an undefined handover.
• Retain the record and the receipt of every report filed. This forms a traceable chain of evidence that can be produced intact during inspections or cross-checks, without relying on reconstruction from correspondence.
• Link vigilance data to batch records. The association makes cross-verification and traceability straightforward when the authority compares reports with sampling or distribution data.
• Review the operational effectiveness of the vigilance system periodically. Produce an annual review record, so that effectiveness is demonstrated by documents rather than asserted by memory.

5. Verification checklist

• □ The mandatory problem reporting form prescribed in Section 8 of the guidelines has been obtained
• □ A closed-loop process of problem identification, assessment and reporting has been established
• □ The record and receipt of each report have been retained
• □ Vigilance data have been linked to batch records
• □ An annual review mechanism for the vigilance system has been established
• □ The division of reporting duties between manufacturer and holder has been defined
• □ The items have been incorporated into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com